Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRaphael Pharmaceutical Inc.

Raphael Pharmaceutical Inc.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
1.51 USD 0.00(0%)
Last update at 2026-11-05T21:00:00Z
VOLUME
100
Market Cap
28.25M

Momentum Score

…

Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.51
Low
1.51
High
52 Week Price Range
0.22
Low
1.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Raphael Pharmaceutical Inc. is a publicly traded, early-stage pharmaceutical company listed on the OTCQB with limited public disclosure about its pipeline and operations. Long-term growth depends on advancing clinical programs, achieving regulatory approvals and securing strategic partnerships or funding, and investors may find potential upside if clinical progress and capitalization improve.
Key risks are early-stage clinical and regulatory uncertainty, likely operating losses and future financing needs that could dilute shareholders and slow development.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.51
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-688.47%
Net Debt
0.02M
ROCE
86.88%
Diluted EPS TTM
-0.05

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1.28M -1.52M -1.34M -3.36M -1.62M
Net income -1.28M -1.52M -1.34M -3.36M -1.62M
Selling general administrative 0.61M 0.73M 0.76M 2.14M 0.85M
Ebit - - - -3.32M -1.63M
Ebitda - - - -3.32M -1.63M
Operating income -1.25M -1.51M -1.33M -3.32M -1.63M
Interest expense 0.02M - - - -
Net interest income -0.02M -0.00M -0.00M -0.04M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.25M 1.51M 1.33M 3.32M 1.63M
Total other income expense net -0.02M -0.01M -0.01M - -
Net income from continuing ops -1.28M -1.52M -1.34M -3.36M -1.62M
Net income applicable to common shares - - - -3.36M -1.62M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.05M 0.03M 0.24M 0.33M 0.42M
Other current assets - - - 0.04M -
Total liab 1.49M 0.77M 0.13M 0.23M 0.29M
Total stockholder equity -1.43M -0.74M 0.11M 0.11M 0.13M
Other current liab - - - 0.22M -
Common stock - - - 0.16M 0.13M
Capital stock 0.20M 0.19M 0.18M 0.16M 0.13M
Retained earnings -10.17M -8.89M -7.37M -6.03M -2.67M
Cash 0.04M 0.02M 0.23M 0.29M 0.15M
Total current liabilities 1.49M 0.77M 0.13M 0.23M 0.29M
Net debt - 0.02M - - -
Short long term debt 0.03M 0.04M - - -
Property plant equipment - - - 0.00M -
Total current assets 0.05M 0.03M 0.24M 0.33M 0.42M
Net tangible assets - - - 0.11M 0.13M
Net receivables - - - - 0.09M
Accounts payable 0.16M 0.12M 0.07M 0.07M 0.11M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.00M -0.00M -
Change to liabilities - - - 0.10M 0.23M
Total cashflows from investing activities - - - -0.00M -0.00M
Net borrowings -0.01M 0.04M 0.00M - 0.17M
Total cash from financing activities 0.24M 0.32M 1.15M 0.90M 1.48M
Change to operating activities - - - 0.21M -0.03M
Net income -1.28M -1.52M -1.34M -3.36M -1.62M
Change in cash 0.03M -0.21M -0.06M 0.14M 0.06M
Begin period cash flow 0.02M 0.23M 0.29M 0.15M 0.10M
End period cash flow 0.04M 0.02M 0.23M 0.29M 0.15M
Total cash from operating activities -0.21M -0.53M -1.20M -0.76M -1.42M
Issuance of capital stock 0.24M 0.28M 1.15M 0.90M 1.29M
Other cashflows from financing activities - - - - 0.01M
Change to netincome - - - 2.29M 2.29M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.82M 0.60M -0.06M 0.31M 0.21M
Stock based compensation 0.24M 0.39M 0.20M 2.29M -
Free cash flow -0.21M -0.53M -1.20M -0.76M -1.42M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
RAPH
Raphael Pharmaceutical Inc.		 -
-%		 1.51 - - - 304.45 -14.44
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 23.11

Profile*

Raphael Pharmaceutical Inc.

Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.

4 Lui Paster, Jaffa, Israel, 6803605

972 5 2775 5072

https://www.raphaelpharmaceutical.com

Name Title Year Born
Mr. Shlomo Pilo CEO & Director 1955
Dr. Igal Louria Hayon Chief Technology Officer 1973
Mr. Uri Tadelis Chief Financial Officer & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…